In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).

The talk focuses on the evidence for short- and long-term benefits of achieving and maintaining glycemic control in patients with T2D, and discusses options for lifestyle and medication management to achieve such control. Randomized controlled trials that will provide new information about optimal management approaches, such as the NIH's GRADE trial, will be discussed. In particular, the results of recent Cardiovascular Outcomes Trials for newer diabetes medications highlight the importance of CV prevention in patients with T2DM.

This session will review a number of clinically relevant trials/topics recently presented at the American College of Cardiology Scientific Sessions in March 2017, including updates in the management of patients with hypercholesterolemia, heart failure, valvular heart disease, arrhythmias, and more.

In this expert perspective, Dr. Richard E. Pratley shares strategies for designing insulin regimens that are individualized based upon patient-specific factors. He will also describe the differences between conventional basal insulin products and new-generation basal insulin products, and how to appropriately initiate and titrate newer basal insulin products.

This series of interactive cases will provide an opportunity for the learner to increase their knowledge in the management of people with type 2 diabetes on insulin therapy. The cases will illustrate expert guidelines and general strategies around use of insulin and combinations of injectables for type 2 diabetes, including a practical approach to the initiation and intensification of basal insulin. You will learn the advantages and disadvantages of combination injectable medications as well as how to use them safely and appropriately.

Primary care clinicians (PCCs) are ideally suited to educate and advise people with type 2 diabetes about basal insulin. This program will inform PCCs about current recommendations and advances in the safe and effective use of basal insulin, so they can provide individualized, appropriate care for their patients.

In this case presentation, Dr. Lee shares strategies for designing basal insulin regimens considering patient comorbidities and socioeconomic factors, highlights the differences between conventional and newer basal insulins, and describes how to appropriately initiate and dose newer basal insulin products in patients with type 2 diabetes.

Primary care clinicians (PCCs) are ideally suited to educate and advise people with type 2 diabetes about basal insulin. This program will inform PCCs about current recommendations and advances in the safe and effective use of basal insulin, so they can provide individualized, appropriate care for their patients.

This talk will provide an opportunity for the learner to (anonymously) test his/her knowledge in the management of people with type 2 diabetes using cases and an ARS. The cases will also be used to illustrate the pathophysiology of type 2 diabetes and provide an opportunity for developing a practical approach to treating people with type 2 diabetes, utilizing the commonest and newest medications available. The cases will also help the learners use medications safely and understand advantages and disadvantages, and common side effects of each class of medication. Finally a practical approach to the initiation and intensification of basal insulin will be covered.

Individualized care is crucial to successful type 2 diabetes (T2DM) management. The emergence of newer oral therapies that not only help to improve glycemic control but also reduce cardiovascular and other risks has dramatically changed the landscape of diabetes care. Understanding when and how to intensify treatment with this expanded toolbox is challenging for clinicians. By reviewing the latest guidelines and clinical data, participants will receive practical strategies to maximize and combine oral therapies, increase adherence, and individualize care in the treatment of diabetes.

Primary care clinicians (PCCs) are ideally suited to educate and advise people with type 2 diabetes about basal insulin. This program will inform PCCs about current recommendations and advances in the safe and effective use of basal insulin, so they can provide individualized, appropriate care for their patients.